Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
about
Influence of immunoglobulin isotype on therapeutic antibody functionImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationImmune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinomaTargeting the tumor microenvironment to enhance antitumor immune responsesInduction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T CellsAnti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking.Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.The Use of Anti-CD40 mAb in Cancer.Kaposi sarcoma-associated herpesvirus latency locus renders B cells hyperresponsive to secondary infectionsBispecific antibodies in cancer immunotherapy
P2860
Q26772080-DAAA2445-2032-4399-B69E-9D536BA6C2CAQ28068378-FAA068F8-5ECB-4505-8F17-6DA26AAD5039Q34458339-4C722ACE-7E82-4014-8B49-8018D62C77C7Q34978570-8342885E-9ECF-42C5-8200-F0FBEDAD2315Q35068131-A886B29B-B547-4E25-95E6-85CDC5111339Q35176307-CB1371FB-9021-410B-BE91-1AB22B7F7782Q35329190-1EEA42BD-5B1A-40F2-A5F9-CB78F21D042AQ35864569-3A6F77DF-C01A-42BD-9A3E-CC0CF6A168ABQ37114367-4F68B147-1B99-4F07-8945-3740964A1BA9Q37155745-E965CF43-DC44-4CDD-8156-FB7EE43FCB07Q38770814-41645ABB-39E9-48D2-ADF0-DBFB4B2BFBCDQ38786054-6E4576F6-0829-4714-AB8E-2AD14F285163Q42316769-C8E7C3F9-7C68-45AA-B51A-DFB3F70D2D6FQ42729928-7CAF3088-68A5-43BD-9C43-3E1452534BD7Q50045161-7470E292-49A9-4DC1-9DD4-CA33CD0B0F77Q52342639-02EBE7F7-DE37-4226-9E43-0A04B94090F2Q52726024-2360C5F2-3ECA-43B8-976E-A4B5667CCF55Q53321210-90BFE38E-1B4E-409F-B0A6-9D4946BCCAA4Q56345322-601D04F6-1C73-4811-84E2-992150A5EB7FQ56893015-0EE630B2-EE06-47A6-A829-807CC992A60D
P2860
Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Role of crosslinking for agoni ...... s as immune therapy of cancer.
@en
type
label
Role of crosslinking for agoni ...... s as immune therapy of cancer.
@en
prefLabel
Role of crosslinking for agoni ...... s as immune therapy of cancer.
@en
P2860
P1476
Role of crosslinking for agoni ...... s as immune therapy of cancer.
@en
P2093
Lee P Richman
Robert H Vonderheide
P2860
P356
10.1158/2326-6066.CIR-13-0152
P577
2014-01-01T00:00:00Z